Sarepta Therapeutics Inc. (SRPT) on Wednesday reported second-quarter net income of $196.9 million. On a per-share basis, the ...

Shares of Sarepta Therapeutics (NASDAQ:SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...

At the U.S. Food and Drug Administration's (FDA) request, Vinay Prasad is returning to the role of director of the Center for ...

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +81.98% and +15.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Vinay Prasad is returning to his role overseeing vaccine, gene therapy and blood product regulation at the U.S. Food and Drug ...

Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...

Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their ...

Analysts expect Sarepta Therapeutics to report an earnings per share (EPS) of $1.01. The announcement from Sarepta ...

Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta's most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. As ...

Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Sarepta between June 22, 2023 and June 24, 2025 ...

U.S. stocks appear set for a positive opening on Thursday as President Donald Trump’s deadline for reciprocal tariffs kicked ...